80 related articles for article (PubMed ID: 23112064)
1. FDA raises concerns about ultra-long acting insulins given green light in Europe and Japan.
Torjesen I
BMJ; 2012 Oct; 345():e7323. PubMed ID: 23112064
[No Abstract] [Full Text] [Related]
2. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin.
Schmidt TA; Rosen CJ; Yudkin JS
BMJ; 2013 Jun; 346():f3731. PubMed ID: 23757746
[No Abstract] [Full Text] [Related]
3. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
4. FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
[No Abstract] [Full Text] [Related]
5. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
6. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
7. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
Freemantle N
BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
[No Abstract] [Full Text] [Related]
8. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
9. Warning: dangers of insulin at 200 units per ml.
Prescrire Int; 2014 Apr; 23(148):111. PubMed ID: 24860907
[No Abstract] [Full Text] [Related]
10. Cardiovascular safety and diabetes drug development.
Drucker DJ; Goldfine AB
Lancet; 2011 Mar; 377(9770):977-9. PubMed ID: 21316097
[No Abstract] [Full Text] [Related]
11. The oral hypoglycemic controversy. Stay as sweet as you are.
Gregory DR
Leg Aspects Med Pract; 1979 Mar; 7(3):16-9. PubMed ID: 106193
[No Abstract] [Full Text] [Related]
12. Drug safety. Planned study of Avandia in doubt after FDA review.
Kean S
Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
[No Abstract] [Full Text] [Related]
13. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
[No Abstract] [Full Text] [Related]
14. Is the FDA on drugs?
Calabresi M; Park A
Time; 2010 Aug; 176(8):24-8. PubMed ID: 20821962
[No Abstract] [Full Text] [Related]
15. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
16. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
17. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
18. The rosiglitazone decision process at FDA and EMA. What should we learn?
Pouwels KB; van Grootheest K
Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
[TBL] [Abstract][Full Text] [Related]
19. [Hypersensitization to protamine-containing insulin].
Räsänen L; Tuomi ML; Lahtela J; Knip M
Duodecim; 1995; 111(10):914-8. PubMed ID: 9081826
[No Abstract] [Full Text] [Related]
20. [Clinical use of long-acting insulin analogs].
Birkeland KI
Tidsskr Nor Laegeforen; 2006 Apr; 126(8):1067-8. PubMed ID: 16619068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
